FDA didn't pull OZOBAX; generics are coming

Key points

• The FDA has determined that the muscle relaxant OZOBAX was not withdrawn from the market due to safety or effectiveness concerns.
• This decision clears the way for pharmaceutical companies to manufacture and sell cheaper, generic versions of the baclofen oral solution.
• The FDA's action is a standard part of the process for approving generic drugs when a brand-name equivalent has been discontinued.
• Consumers and patients are likely to benefit from lower prices once generic versions become available.
• The next step to watch for is the FDA's official approval of the first generic competitor to OZOBAX.

This report is part of Foodie Pundit premium coverage. Foodie Pundit members read the full story. See membership.

More from the Foodie Pundit Newsroom

• FDA is messing with your food ingredients again
• Mark Best Is Teasing A Florida Restaurant. Here's What That Means.
• FDA just upped your pre-cut salad safety
• Is Walla Walla About to Get a New Wine Region?
• Feds offload Cherokee forest, goodbye ramps and morels